 across its scientific and operational workflows.){kind=link}
Thermo Fisher Scientific is deepening its investment in digital transformation with a new collaboration with OpenAI, aimed at expanding the role of artificial intelligence (AI) across its scientific and operational workflows. The initiative seeks to accelerate the pace of drug discovery and development, ultimately helping biopharma customers deliver new therapies to patients more efficiently and cost-effectively.
AI is shaping the future of science. And when combined with our Mission to enable our customers to make the world healthier, cleaner and safer, it is a powerful catalyst to accelerate scientific advancement. With OpenAI, we’re further embedding AI across our operations, products and services. Together, we’re building an ecosystem that accelerates scientific breakthroughs and delivers impact for customers, patients and society.
Marc Casper, Chairman, President and Chief Executive Officer, Thermo Fisher Scientific
Under the partnership, Thermo Fisher will integrate OpenAI’s API technology into key areas of its global operations, including product development, customer engagement, service delivery, and internal process optimization. By embedding large language model capabilities into its ecosystem, the company aims to streamline data analysis, improve decision-making speed, and reduce the complexity of research and development pipelines.
Thermo Fisher plays a massive role in advancing science, and together we have an opportunity to accelerate how medicine can reach more people. With OpenAI directly powering Thermo Fisher workflows, frontier AI can help cut through complexity, speed up breakthroughs, and bring real impact to patients’ lives.
Brad Lightcap, chief operating officer at OpenAI
The collaboration will:
- Deploy OpenAI advanced capabilities to one of the highest impact initial focus areas – Thermo Fisher’s industry leading PPD™ clinical research business – to significantly improve the cycle time of clinical trials and accelerate the time to bring new medicines to market, creating meaningful value for the industry.
- Leverage OpenAI capabilities and Thermo Fisher’s expertise, to more quickly help identify therapies that are unlikely to succeed, which will enable customers to redirect investment and resources toward more promising opportunities.
- Integrate AI into Thermo Fisher’s Accelerator™ Drug Development solution, an end-to-end approach spanning early development, Phase I–III clinical research, clinical manufacturing and supply and commercialization. This solution is designed to deliver greater speed, simplicity and scalability for customers.
- Launch frontier AI to Thermo Fisher colleagues, with ChatGPT Enterprise, making it easier to build confidence and fluency with these powerful tools.